#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Bacterial Membrane Vesicles , which respond to the extracellular vesicles (
3-1	17-26	Bacterial	object[4]	new[4]	coref	3-8[5_4]
3-2	27-35	Membrane	object|object[4]	new|new[4]	coref	4-7
3-3	36-44	Vesicles	object[4]	new[4]	_	_
3-4	45-46	,	_	_	_	_
3-5	47-52	which	_	_	_	_
3-6	53-60	respond	_	_	_	_
3-7	61-63	to	_	_	_	_
3-8	64-67	the	object[5]	giv[5]	_	_
3-9	68-81	extracellular	object[5]	giv[5]	_	_
3-10	82-90	vesicles	object[5]	giv[5]	_	_
3-11	91-92	(	abstract[8]	new[8]	coref	4-7[10_8]

#Text=EVs ) definition criteria , are membrane structures , produced by Gram-negative , Gram-positive and Mycobacteria microorganisms during their growth .
4-1	93-96	EVs	abstract|abstract[8]	new|new[8]	coref	6-6
4-2	97-98	)	abstract[8]	new[8]	_	_
4-3	99-109	definition	abstract|abstract[8]	new|new[8]	_	_
4-4	110-118	criteria	abstract[8]	new[8]	_	_
4-5	119-120	,	_	_	_	_
4-6	121-124	are	_	_	_	_
4-7	125-133	membrane	object|abstract[10]	giv|giv[10]	coref|coref	8-9[52_0]|8-9[52_0]
4-8	134-144	structures	abstract[10]	giv[10]	_	_
4-9	145-146	,	_	_	_	_
4-10	147-155	produced	_	_	_	_
4-11	156-158	by	_	_	_	_
4-12	159-172	Gram-negative	substance	new	coref	18-53[185_0]
4-13	173-174	,	_	_	_	_
4-14	175-188	Gram-positive	animal[12]	new[12]	ana	4-19[0_12]
4-15	189-192	and	animal[12]	new[12]	_	_
4-16	193-205	Mycobacteria	animal[12]	new[12]	_	_
4-17	206-220	microorganisms	animal[12]	new[12]	_	_
4-18	221-227	during	_	_	_	_
4-19	228-233	their	animal|abstract[14]	giv|new[14]	coref|coref	10-33[0_14]|10-33[0_14]
4-20	234-240	growth	abstract[14]	new[14]	_	_
4-21	241-242	.	_	_	_	_

#Text=These elements are spherical in shape , with an average size in the range from 20 to 500 nm and deliver several components , such as proteins , nucleic acids , and phospholipids .
5-1	243-248	These	object[15]	new[15]	_	_
5-2	249-257	elements	object[15]	new[15]	_	_
5-3	258-261	are	_	_	_	_
5-4	262-271	spherical	_	_	_	_
5-5	272-274	in	_	_	_	_
5-6	275-280	shape	abstract	new	_	_
5-7	281-282	,	_	_	_	_
5-8	283-287	with	_	_	_	_
5-9	288-290	an	abstract[17]	new[17]	_	_
5-10	291-298	average	abstract[17]	new[17]	_	_
5-11	299-303	size	abstract[17]	new[17]	_	_
5-12	304-306	in	abstract[17]	new[17]	_	_
5-13	307-310	the	abstract[17]|abstract[18]	new[17]|new[18]	ana	6-1[0_18]
5-14	311-316	range	abstract[17]|abstract[18]	new[17]|new[18]	_	_
5-15	317-321	from	abstract[17]|abstract[18]	new[17]|new[18]	_	_
5-16	322-324	20	abstract[17]|abstract[18]|quantity	new[17]|new[18]|new	_	_
5-17	325-327	to	_	_	_	_
5-18	328-331	500	quantity[20]	new[20]	_	_
5-19	332-334	nm	quantity[20]	new[20]	_	_
5-20	335-338	and	_	_	_	_
5-21	339-346	deliver	_	_	_	_
5-22	347-354	several	abstract[21]	new[21]	_	_
5-23	355-365	components	abstract[21]	new[21]	_	_
5-24	366-367	,	abstract[21]	new[21]	_	_
5-25	368-372	such	abstract[21]	new[21]	_	_
5-26	373-375	as	abstract[21]	new[21]	_	_
5-27	376-384	proteins	abstract[21]|substance	new[21]|new	_	_
5-28	385-386	,	abstract[21]	new[21]	_	_
5-29	387-394	nucleic	abstract[21]|substance[23]	new[21]|new[23]	_	_
5-30	395-400	acids	abstract[21]|substance[23]	new[21]|new[23]	_	_
5-31	401-402	,	abstract[21]	new[21]	_	_
5-32	403-406	and	abstract[21]	new[21]	_	_
5-33	407-420	phospholipids	abstract[21]|substance	new[21]|new	_	_
5-34	421-422	.	_	_	_	_

#Text=It has been reported that EVs are involved in a number of physiological and pathological mechanisms , including biofilm formation , inter-cellular cross-talk , as well as bacteria – host and bacterium – phage interactions .
6-1	423-425	It	abstract	giv	_	_
6-2	426-429	has	_	_	_	_
6-3	430-434	been	_	_	_	_
6-4	435-443	reported	_	_	_	_
6-5	444-448	that	_	_	_	_
6-6	449-452	EVs	abstract	giv	coref	7-10
6-7	453-456	are	_	_	_	_
6-8	457-465	involved	_	_	_	_
6-9	466-468	in	_	_	_	_
6-10	469-470	a	abstract[27]	new[27]	_	_
6-11	471-477	number	abstract[27]	new[27]	_	_
6-12	478-480	of	abstract[27]	new[27]	_	_
6-13	481-494	physiological	abstract[27]	new[27]	_	_
6-14	495-498	and	abstract[27]	new[27]	_	_
6-15	499-511	pathological	abstract[27]	new[27]	_	_
6-16	512-522	mechanisms	abstract[27]	new[27]	_	_
6-17	523-524	,	abstract[27]	new[27]	_	_
6-18	525-534	including	abstract[27]	new[27]	_	_
6-19	535-542	biofilm	abstract[27]|object|abstract[29]	new[27]|new|new[29]	coref|coref	13-26|13-26
6-20	543-552	formation	abstract[27]|abstract[29]	new[27]|new[29]	_	_
6-21	553-554	,	abstract[27]	new[27]	_	_
6-22	555-569	inter-cellular	abstract[27]|abstract[30]	new[27]|new[30]	_	_
6-23	570-580	cross-talk	abstract[27]|abstract[30]	new[27]|new[30]	_	_
6-24	581-582	,	_	_	_	_
6-25	583-585	as	_	_	_	_
6-26	586-590	well	_	_	_	_
6-27	591-593	as	_	_	_	_
6-28	594-602	bacteria	animal	new	coref	8-24[55_0]
6-29	603-604	–	_	_	_	_
6-30	605-609	host	person	new	_	_
6-31	610-613	and	_	_	_	_
6-32	614-623	bacterium	animal	new	coref	18-70
6-33	624-625	–	_	_	_	_
6-34	626-631	phage	object|abstract[35]	new|new[35]	_	_
6-35	632-644	interactions	abstract[35]	new[35]	_	_
6-36	645-646	.	_	_	_	_

#Text=Many studies support the hypothesis that the generation of EVs is a controlled and regulated process , although Turnbull et al. demonstrated that the EVs ’ biogenesis is associated with a rearrangement of the bacterial membranes , derived from lysed cells , which incorporate soluble molecules .
7-1	647-651	Many	abstract[36]	new[36]	_	_
7-2	652-659	studies	abstract[36]	new[36]	_	_
7-3	660-667	support	_	_	_	_
7-4	668-671	the	abstract[37]	new[37]	_	_
7-5	672-682	hypothesis	abstract[37]	new[37]	_	_
7-6	683-687	that	abstract[37]	new[37]	_	_
7-7	688-691	the	abstract[37]|event[38]	new[37]|new[38]	coref	7-12[40_38]
7-8	692-702	generation	abstract[37]|event[38]	new[37]|new[38]	_	_
7-9	703-705	of	abstract[37]|event[38]	new[37]|new[38]	_	_
7-10	706-709	EVs	abstract[37]|event[38]|object	new[37]|new[38]|giv	coref	8-6
7-11	710-712	is	abstract[37]	new[37]	_	_
7-12	713-714	a	abstract[37]|event[40]	new[37]|giv[40]	coref	11-28[88_40]
7-13	715-725	controlled	abstract[37]|event[40]	new[37]|giv[40]	_	_
7-14	726-729	and	abstract[37]|event[40]	new[37]|giv[40]	_	_
7-15	730-739	regulated	abstract[37]|event[40]	new[37]|giv[40]	_	_
7-16	740-747	process	abstract[37]|event[40]	new[37]|giv[40]	_	_
7-17	748-749	,	_	_	_	_
7-18	750-758	although	_	_	_	_
7-19	759-767	Turnbull	person	new	_	_
7-20	768-770	et	_	_	_	_
7-21	771-774	al.	_	_	_	_
7-22	775-787	demonstrated	_	_	_	_
7-23	788-792	that	_	_	_	_
7-24	793-796	the	abstract[43]	new[43]	ana	8-1[0_43]
7-25	797-800	EVs	abstract[42]|abstract[43]	new[42]|new[43]	_	_
7-26	801-802	’	abstract[42]|abstract[43]	new[42]|new[43]	_	_
7-27	803-813	biogenesis	abstract[43]	new[43]	_	_
7-28	814-816	is	_	_	_	_
7-29	817-827	associated	_	_	_	_
7-30	828-832	with	_	_	_	_
7-31	833-834	a	event[44]	new[44]	_	_
7-32	835-848	rearrangement	event[44]	new[44]	_	_
7-33	849-851	of	event[44]	new[44]	_	_
7-34	852-855	the	event[44]|object[46]	new[44]|new[46]	_	_
7-35	856-865	bacterial	event[44]|substance|object[46]	new[44]|new|new[46]	coref	10-23
7-36	866-875	membranes	event[44]|object[46]	new[44]|new[46]	_	_
7-37	876-877	,	_	_	_	_
7-38	878-885	derived	_	_	_	_
7-39	886-890	from	_	_	_	_
7-40	891-896	lysed	object[47]	new[47]	coref	8-13[53_47]
7-41	897-902	cells	object[47]	new[47]	_	_
7-42	903-904	,	_	_	_	_
7-43	905-910	which	_	_	_	_
7-44	911-922	incorporate	_	_	_	_
7-45	923-930	soluble	substance[48]	new[48]	_	_
7-46	931-940	molecules	substance[48]	new[48]	_	_
7-47	941-942	.	_	_	_	_

#Text=It is also known that EVs fuse with the outer membrane of Gram-negative cells , while they are not able to interact with Gram-positive bacteria .
8-1	943-945	It	abstract	giv	_	_
8-2	946-948	is	_	_	_	_
8-3	949-953	also	_	_	_	_
8-4	954-959	known	_	_	_	_
8-5	960-964	that	_	_	_	_
8-6	965-968	EVs	abstract|abstract[51]	giv|new[51]	ana|coref|ana|coref	9-1[0_51]|9-5|9-1[0_51]|9-5
8-7	969-973	fuse	abstract[51]	new[51]	_	_
8-8	974-978	with	abstract[51]	new[51]	_	_
8-9	979-982	the	abstract[51]|object[52]	new[51]|giv[52]	_	_
8-10	983-988	outer	abstract[51]|object[52]	new[51]|giv[52]	_	_
8-11	989-997	membrane	abstract[51]|object[52]	new[51]|giv[52]	_	_
8-12	998-1000	of	abstract[51]|object[52]	new[51]|giv[52]	_	_
8-13	1001-1014	Gram-negative	abstract[51]|object[52]|object[53]	new[51]|giv[52]|giv[53]	ana	8-17[0_53]
8-14	1015-1020	cells	abstract[51]|object[52]|object[53]	new[51]|giv[52]|giv[53]	_	_
8-15	1021-1022	,	_	_	_	_
8-16	1023-1028	while	_	_	_	_
8-17	1029-1033	they	object	giv	ana	9-18
8-18	1034-1037	are	_	_	_	_
8-19	1038-1041	not	_	_	_	_
8-20	1042-1046	able	_	_	_	_
8-21	1047-1049	to	_	_	_	_
8-22	1050-1058	interact	_	_	_	_
8-23	1059-1063	with	_	_	_	_
8-24	1064-1077	Gram-positive	animal[55]	giv[55]	_	_
8-25	1078-1086	bacteria	animal[55]	giv[55]	_	_
8-26	1087-1088	.	_	_	_	_

#Text=It was demonstrated that EVs stemming from Pseudomonas aeruginosa are able to interact with Shigella flexneri pouring their content into the periplasm of eukaryotic cells ; conversely , EVs derived from P. aeruginosa adhere to the cell wall of Staphylococcus aureus .
9-1	1089-1091	It	abstract	giv	_	_
9-2	1092-1095	was	_	_	_	_
9-3	1096-1108	demonstrated	_	_	_	_
9-4	1109-1113	that	_	_	_	_
9-5	1114-1117	EVs	abstract	giv	coref	9-27[64_0]
9-6	1118-1126	stemming	_	_	_	_
9-7	1127-1131	from	_	_	_	_
9-8	1132-1143	Pseudomonas	place	new	_	_
9-9	1144-1154	aeruginosa	_	_	_	_
9-10	1155-1158	are	_	_	_	_
9-11	1159-1163	able	_	_	_	_
9-12	1164-1166	to	_	_	_	_
9-13	1167-1175	interact	_	_	_	_
9-14	1176-1180	with	_	_	_	_
9-15	1181-1189	Shigella	person	new	_	_
9-16	1190-1198	flexneri	_	_	_	_
9-17	1199-1206	pouring	_	_	_	_
9-18	1207-1212	their	object|abstract[61]	giv|new[61]	coref|coref|coref|coref	9-24[63_0]|10-5[0_61]|9-24[63_0]|10-5[0_61]
9-19	1213-1220	content	abstract[61]	new[61]	_	_
9-20	1221-1225	into	_	_	_	_
9-21	1226-1229	the	place[62]	new[62]	_	_
9-22	1230-1239	periplasm	place[62]	new[62]	_	_
9-23	1240-1242	of	place[62]	new[62]	_	_
9-24	1243-1253	eukaryotic	place[62]|object[63]	new[62]|giv[63]	coref	11-55[98_63]
9-25	1254-1259	cells	place[62]|object[63]	new[62]|giv[63]	_	_
9-26	1260-1261	;	_	_	_	_
9-27	1262-1272	conversely	abstract[64]	giv[64]	coref	10-2[0_64]
9-28	1273-1274	,	abstract[64]	giv[64]	_	_
9-29	1275-1278	EVs	abstract[64]	giv[64]	_	_
9-30	1279-1286	derived	_	_	_	_
9-31	1287-1291	from	_	_	_	_
9-32	1292-1294	P.	_	_	_	_
9-33	1295-1305	aeruginosa	_	_	_	_
9-34	1306-1312	adhere	_	_	_	_
9-35	1313-1315	to	_	_	_	_
9-36	1316-1319	the	place[66]	new[66]	_	_
9-37	1320-1324	cell	place|place[66]	new|new[66]	_	_
9-38	1325-1329	wall	place[66]	new[66]	_	_
9-39	1330-1332	of	place[66]	new[66]	_	_
9-40	1333-1347	Staphylococcus	place[66]	new[66]	_	_
9-41	1348-1354	aureus	place[66]	new[66]	_	_
9-42	1355-1356	.	_	_	_	_

#Text=The EVs composition and content are strictly dependent on the environmental conditions where they are generated , as well as on the bacterial species from which they are produced and on their growth phase .
10-1	1357-1360	The	abstract[68]	new[68]	coref	13-31[118_68]
10-2	1361-1364	EVs	abstract|abstract[68]	giv|new[68]	coref	11-8
10-3	1365-1376	composition	abstract[68]	new[68]	_	_
10-4	1377-1380	and	_	_	_	_
10-5	1381-1388	content	abstract	giv	coref	13-8
10-6	1389-1392	are	_	_	_	_
10-7	1393-1401	strictly	_	_	_	_
10-8	1402-1411	dependent	_	_	_	_
10-9	1412-1414	on	_	_	_	_
10-10	1415-1418	the	abstract[70]	new[70]	ana	10-14[0_70]
10-11	1419-1432	environmental	abstract[70]	new[70]	_	_
10-12	1433-1443	conditions	abstract[70]	new[70]	_	_
10-13	1444-1449	where	_	_	_	_
10-14	1450-1454	they	abstract	giv	ana	10-27
10-15	1455-1458	are	_	_	_	_
10-16	1459-1468	generated	_	_	_	_
10-17	1469-1470	,	_	_	_	_
10-18	1471-1473	as	_	_	_	_
10-19	1474-1478	well	_	_	_	_
10-20	1479-1481	as	_	_	_	_
10-21	1482-1484	on	_	_	_	_
10-22	1485-1488	the	abstract[73]	new[73]	ana	11-61[0_73]
10-23	1489-1498	bacterial	animal|abstract[73]	giv|new[73]	coref	11-56
10-24	1499-1506	species	abstract[73]	new[73]	_	_
10-25	1507-1511	from	_	_	_	_
10-26	1512-1517	which	_	_	_	_
10-27	1518-1522	they	abstract	giv	ana	10-32
10-28	1523-1526	are	_	_	_	_
10-29	1527-1535	produced	_	_	_	_
10-30	1536-1539	and	_	_	_	_
10-31	1540-1542	on	_	_	_	_
10-32	1543-1548	their	abstract|abstract[77]	giv|new[77]	coref|coref|coref|coref	11-4[78_0]|13-14[112_77]|11-4[78_0]|13-14[112_77]
10-33	1549-1555	growth	abstract|abstract[77]	giv|new[77]	coref	13-15
10-34	1556-1561	phase	abstract[77]	new[77]	_	_
10-35	1562-1563	.	_	_	_	_

#Text=For example , iron-limiting conditions increase the EVs production from Helicobacter pylori , Haemophilus influenzae , Escherichia coli , and Vibrio cholera ; the oxygen availability affects the generation of EVs and the antibiotic treatment ( i. e. , polymyxin B or colistin ) promotes an increase of EVs production that confers protection to the bacterial cells , thus allowing their survival .
11-1	1564-1567	For	_	_	_	_
11-2	1568-1575	example	_	_	_	_
11-3	1576-1577	,	_	_	_	_
11-4	1578-1591	iron-limiting	abstract[78]	giv[78]	coref	19-19[196_78]
11-5	1592-1602	conditions	abstract[78]	giv[78]	_	_
11-6	1603-1611	increase	_	_	_	_
11-7	1612-1615	the	abstract[80]	new[80]	coref	11-49[95_80]
11-8	1616-1619	EVs	object|abstract[80]	giv|new[80]	coref	11-31
11-9	1620-1630	production	abstract[80]	new[80]	_	_
11-10	1631-1635	from	abstract[80]	new[80]	_	_
11-11	1636-1648	Helicobacter	abstract[80]|person|substance[82]	new[80]|new|new[82]	coref|coref|coref|coref	14-1|14-1[131_82]|14-1|14-1[131_82]
11-12	1649-1655	pylori	abstract[80]|substance[82]	new[80]|new[82]	_	_
11-13	1656-1657	,	abstract[80]	new[80]	_	_
11-14	1658-1669	Haemophilus	abstract[80]|abstract	new[80]|new	_	_
11-15	1670-1680	influenzae	abstract[80]	new[80]	_	_
11-16	1681-1682	,	abstract[80]	new[80]	_	_
11-17	1683-1694	Escherichia	abstract[80]	new[80]	_	_
11-18	1695-1699	coli	abstract[80]	new[80]	_	_
11-19	1700-1701	,	abstract[80]	new[80]	_	_
11-20	1702-1705	and	abstract[80]	new[80]	_	_
11-21	1706-1712	Vibrio	abstract[80]|person|animal[85]	new[80]|new|new[85]	_	_
11-22	1713-1720	cholera	abstract[80]|animal[85]	new[80]|new[85]	_	_
11-23	1721-1722	;	_	_	_	_
11-24	1723-1726	the	abstract[87]	new[87]	_	_
11-25	1727-1733	oxygen	substance|abstract[87]	new|new[87]	_	_
11-26	1734-1746	availability	abstract[87]	new[87]	_	_
11-27	1747-1754	affects	_	_	_	_
11-28	1755-1758	the	event[88]	giv[88]	_	_
11-29	1759-1769	generation	event[88]	giv[88]	_	_
11-30	1770-1772	of	event[88]	giv[88]	_	_
11-31	1773-1776	EVs	event[88]|abstract	giv[88]|giv	coref	11-49
11-32	1777-1780	and	_	_	_	_
11-33	1781-1784	the	abstract[91]	new[91]	coref	12-12[103_91]
11-34	1785-1795	antibiotic	substance|abstract[91]	new|new[91]	_	_
11-35	1796-1805	treatment	abstract[91]	new[91]	_	_
11-36	1806-1807	(	_	_	_	_
11-37	1808-1810	i.	_	_	_	_
11-38	1811-1813	e.	_	_	_	_
11-39	1814-1815	,	_	_	_	_
11-40	1816-1825	polymyxin	_	_	_	_
11-41	1826-1827	B	_	_	_	_
11-42	1828-1830	or	_	_	_	_
11-43	1831-1839	colistin	object	new	_	_
11-44	1840-1841	)	_	_	_	_
11-45	1842-1850	promotes	_	_	_	_
11-46	1851-1853	an	quantity[93]	new[93]	_	_
11-47	1854-1862	increase	quantity[93]	new[93]	_	_
11-48	1863-1865	of	quantity[93]	new[93]	_	_
11-49	1866-1869	EVs	quantity[93]|abstract|abstract[95]	new[93]|giv|giv[95]	coref|coref|coref|coref	12-16[104_95]|12-19|12-16[104_95]|12-19
11-50	1870-1880	production	quantity[93]|abstract[95]	new[93]|giv[95]	_	_
11-51	1881-1885	that	_	_	_	_
11-52	1886-1893	confers	_	_	_	_
11-53	1894-1904	protection	abstract	new	_	_
11-54	1905-1907	to	_	_	_	_
11-55	1908-1911	the	object[98]	giv[98]	coref	16-13[149_98]
11-56	1912-1921	bacterial	substance|object[98]	giv|giv[98]	coref	13-23
11-57	1922-1927	cells	object[98]	giv[98]	_	_
11-58	1928-1929	,	_	_	_	_
11-59	1930-1934	thus	_	_	_	_
11-60	1935-1943	allowing	_	_	_	_
11-61	1944-1949	their	abstract|event[100]	giv|new[100]	_	_
11-62	1950-1958	survival	event[100]	new[100]	_	_
11-63	1959-1960	.	_	_	_	_

#Text=A previous study , performed on Stenotrophomonas maltophilia , demonstrated that the imipenem treatment increases the production of EVs delivering β-lactamases .
12-1	1961-1962	A	abstract[101]	new[101]	_	_
12-2	1963-1971	previous	abstract[101]	new[101]	_	_
12-3	1972-1977	study	abstract[101]	new[101]	_	_
12-4	1978-1979	,	_	_	_	_
12-5	1980-1989	performed	_	_	_	_
12-6	1990-1992	on	_	_	_	_
12-7	1993-2009	Stenotrophomonas	_	_	_	_
12-8	2010-2021	maltophilia	_	_	_	_
12-9	2022-2023	,	_	_	_	_
12-10	2024-2036	demonstrated	_	_	_	_
12-11	2037-2041	that	_	_	_	_
12-12	2042-2045	the	abstract[103]	giv[103]	_	_
12-13	2046-2054	imipenem	abstract|abstract[103]	new|giv[103]	_	_
12-14	2055-2064	treatment	abstract[103]	giv[103]	_	_
12-15	2065-2074	increases	_	_	_	_
12-16	2075-2078	the	abstract[104]	giv[104]	_	_
12-17	2079-2089	production	abstract[104]	giv[104]	_	_
12-18	2090-2092	of	abstract[104]	giv[104]	_	_
12-19	2093-2096	EVs	abstract[104]|abstract	giv[104]|giv	coref	13-5
12-20	2097-2107	delivering	_	_	_	_
12-21	2108-2120	β-lactamases	substance	new	_	_
12-22	2121-2122	.	_	_	_	_

#Text=Modifications in terms of EVs production and content might also be associated with the growth phase , as well as with the bacterial phenotype ( biofilm or planktonic ) and the media composition . Park et al. demonstrated that EVs associated to the P. aeruginosa biofilm phenotype showed a unique proteome profile , with respect to the one carried by EVs stemming from its planktonic counterpart .
13-1	2123-2136	Modifications	abstract[107]	new[107]	coref	19-13[193_107]
13-2	2137-2139	in	abstract[107]	new[107]	_	_
13-3	2140-2145	terms	abstract[107]	new[107]	_	_
13-4	2146-2148	of	abstract[107]	new[107]	_	_
13-5	2149-2152	EVs	abstract[107]|abstract|abstract[109]	new[107]|giv|new[109]	coref|coref|coref|coref	13-40|19-16[195_109]|13-40|19-16[195_109]
13-6	2153-2163	production	abstract[107]|abstract[109]	new[107]|new[109]	_	_
13-7	2164-2167	and	abstract[107]	new[107]	_	_
13-8	2168-2175	content	abstract[107]|abstract	new[107]|giv	_	_
13-9	2176-2181	might	_	_	_	_
13-10	2182-2186	also	_	_	_	_
13-11	2187-2189	be	_	_	_	_
13-12	2190-2200	associated	_	_	_	_
13-13	2201-2205	with	_	_	_	_
13-14	2206-2209	the	abstract[112]	giv[112]	_	_
13-15	2210-2216	growth	abstract|abstract[112]	giv|giv[112]	_	_
13-16	2217-2222	phase	abstract[112]	giv[112]	_	_
13-17	2223-2224	,	_	_	_	_
13-18	2225-2227	as	_	_	_	_
13-19	2228-2232	well	_	_	_	_
13-20	2233-2235	as	_	_	_	_
13-21	2236-2240	with	_	_	_	_
13-22	2241-2244	the	quantity[114]	new[114]	coref	13-43[122_114]
13-23	2245-2254	bacterial	substance|quantity[114]	giv|new[114]	coref	16-13
13-24	2255-2264	phenotype	quantity[114]	new[114]	_	_
13-25	2265-2266	(	_	_	_	_
13-26	2267-2274	biofilm	substance	giv	coref	13-46
13-27	2275-2277	or	_	_	_	_
13-28	2278-2288	planktonic	abstract	new	coref	15-13[137_0]
13-29	2289-2290	)	_	_	_	_
13-30	2291-2294	and	_	_	_	_
13-31	2295-2298	the	abstract[118]	giv[118]	_	_
13-32	2299-2304	media	abstract|abstract[118]	new|giv[118]	_	_
13-33	2305-2316	composition	abstract[118]	giv[118]	_	_
13-34	2317-2318	.	_	_	_	_
13-35	2319-2323	Park	person	new	_	_
13-36	2324-2326	et	_	_	_	_
13-37	2327-2330	al.	_	_	_	_
13-38	2331-2343	demonstrated	_	_	_	_
13-39	2344-2348	that	_	_	_	_
13-40	2349-2352	EVs	abstract	giv	coref	13-61
13-41	2353-2363	associated	_	_	_	_
13-42	2364-2366	to	_	_	_	_
13-43	2367-2370	the	quantity[122]	giv[122]	coref	17-9[162_122]
13-44	2371-2373	P.	quantity[122]	giv[122]	_	_
13-45	2374-2384	aeruginosa	quantity[122]	giv[122]	_	_
13-46	2385-2392	biofilm	object|quantity[122]	giv|giv[122]	ana	13-64
13-47	2393-2402	phenotype	quantity[122]	giv[122]	_	_
13-48	2403-2409	showed	_	_	_	_
13-49	2410-2411	a	abstract[124]	new[124]	_	_
13-50	2412-2418	unique	abstract[124]	new[124]	_	_
13-51	2419-2427	proteome	abstract|abstract[124]	new|new[124]	_	_
13-52	2428-2435	profile	abstract[124]	new[124]	_	_
13-53	2436-2437	,	_	_	_	_
13-54	2438-2442	with	_	_	_	_
13-55	2443-2450	respect	abstract[125]	new[125]	_	_
13-56	2451-2453	to	abstract[125]	new[125]	_	_
13-57	2454-2457	the	abstract[125]|abstract[126]	new[125]|new[126]	_	_
13-58	2458-2461	one	abstract[125]|abstract[126]	new[125]|new[126]	_	_
13-59	2462-2469	carried	_	_	_	_
13-60	2470-2472	by	_	_	_	_
13-61	2473-2476	EVs	abstract	giv	coref	15-21
13-62	2477-2485	stemming	_	_	_	_
13-63	2486-2490	from	_	_	_	_
13-64	2491-2494	its	substance|object[129]	giv|new[129]	coref|coref	15-18|15-18
13-65	2495-2505	planktonic	object[129]	new[129]	_	_
13-66	2506-2517	counterpart	object[129]	new[129]	_	_
13-67	2518-2519	.	_	_	_	_

#Text=Helicobacter pylori
14-1	2520-2532	Helicobacter	animal|person[131]	giv|giv[131]	_	_
14-2	2533-2539	pylori	person[131]	giv[131]	_	_

#Text=ATCC 43629 and Lactobacillus reuteri DSM 17938 are biofilm-producing strains , and both the planktonic and the biofilm phenotypes generate EVs ( pEVs and bEVs , respectively ) carrying extracellular DNA ( eDNA). .
15-1	2540-2544	ATCC	abstract[132]	new[132]	_	_
15-2	2545-2550	43629	abstract[132]	new[132]	_	_
15-3	2551-2554	and	abstract[132]	new[132]	_	_
15-4	2555-2568	Lactobacillus	abstract[132]|abstract	new[132]|new	_	_
15-5	2569-2576	reuteri	abstract[132]	new[132]	_	_
15-6	2577-2580	DSM	abstract|abstract[135]	new|new[135]	coref|coref	18-67[189_0]|18-67[189_0]
15-7	2581-2586	17938	abstract[135]	new[135]	_	_
15-8	2587-2590	are	_	_	_	_
15-9	2591-2608	biofilm-producing	_	_	_	_
15-10	2609-2616	strains	abstract	new	_	_
15-11	2617-2618	,	_	_	_	_
15-12	2619-2622	and	_	_	_	_
15-13	2623-2627	both	abstract[137]	giv[137]	coref	18-46[182_137]
15-14	2628-2631	the	abstract[137]	giv[137]	_	_
15-15	2632-2642	planktonic	abstract[137]	giv[137]	_	_
15-16	2643-2646	and	_	_	_	_
15-17	2647-2650	the	abstract[139]	new[139]	coref	18-49[184_139]
15-18	2651-2658	biofilm	object|abstract[139]	giv|new[139]	coref	16-48[158_0]
15-19	2659-2669	phenotypes	abstract[139]	new[139]	_	_
15-20	2670-2678	generate	_	_	_	_
15-21	2679-2682	EVs	abstract	giv	appos	15-23[142_0]
15-22	2683-2684	(	_	_	_	_
15-23	2685-2689	pEVs	object|abstract[142]	new|giv[142]	coref|coref	16-32[0_142]|16-32[0_142]
15-24	2690-2693	and	abstract[142]	giv[142]	_	_
15-25	2694-2698	bEVs	abstract[142]|person[143]	giv[142]|new[143]	_	_
15-26	2699-2700	,	abstract[142]|person[143]	giv[142]|new[143]	_	_
15-27	2701-2713	respectively	abstract[142]|person[143]	giv[142]|new[143]	_	_
15-28	2714-2715	)	_	_	_	_
15-29	2716-2724	carrying	_	_	_	_
15-30	2725-2738	extracellular	abstract[144]	new[144]	appos	15-33[0_144]
15-31	2739-2742	DNA	abstract[144]	new[144]	_	_
15-32	2743-2744	(	_	_	_	_
15-33	2745-2751	eDNA).	abstract	giv	_	_
15-34	2752-2753	.	_	_	_	_

#Text=In particular , H. pylori -derived bEVs seemed to “ bridge ” bacterial cells , thus playing a possible structural role ; however , the fact that eDNA are carried by EVs , may protect the eDNA from the enzymatic activity of DNase I in breaking up the biofilm .
16-1	2754-2756	In	_	_	_	_
16-2	2757-2767	particular	_	_	_	_
16-3	2768-2769	,	_	_	_	_
16-4	2770-2772	H.	person[146]	new[146]	coref	18-56[186_146]
16-5	2773-2779	pylori	person[146]	new[146]	_	_
16-6	2780-2788	-derived	_	_	_	_
16-7	2789-2793	bEVs	person	new	_	_
16-8	2794-2800	seemed	_	_	_	_
16-9	2801-2803	to	_	_	_	_
16-10	2804-2805	“	_	_	_	_
16-11	2806-2812	bridge	_	_	_	_
16-12	2813-2814	”	_	_	_	_
16-13	2815-2824	bacterial	substance|object[149]	giv|giv[149]	coref|coref	18-29|18-29
16-14	2825-2830	cells	object[149]	giv[149]	_	_
16-15	2831-2832	,	_	_	_	_
16-16	2833-2837	thus	_	_	_	_
16-17	2838-2845	playing	_	_	_	_
16-18	2846-2847	a	abstract[150]	new[150]	_	_
16-19	2848-2856	possible	abstract[150]	new[150]	_	_
16-20	2857-2867	structural	abstract[150]	new[150]	_	_
16-21	2868-2872	role	abstract[150]	new[150]	_	_
16-22	2873-2874	;	_	_	_	_
16-23	2875-2882	however	abstract[151]	new[151]	_	_
16-24	2883-2884	,	abstract[151]	new[151]	_	_
16-25	2885-2888	the	abstract[151]	new[151]	_	_
16-26	2889-2893	fact	abstract[151]	new[151]	_	_
16-27	2894-2898	that	abstract[151]	new[151]	_	_
16-28	2899-2903	eDNA	abstract[151]|substance	new[151]|new	coref	16-36[154_0]
16-29	2904-2907	are	abstract[151]	new[151]	_	_
16-30	2908-2915	carried	abstract[151]	new[151]	_	_
16-31	2916-2918	by	abstract[151]	new[151]	_	_
16-32	2919-2922	EVs	abstract[151]|substance	new[151]|giv	coref	17-6
16-33	2923-2924	,	abstract[151]	new[151]	_	_
16-34	2925-2928	may	abstract[151]	new[151]	_	_
16-35	2929-2936	protect	abstract[151]	new[151]	_	_
16-36	2937-2940	the	abstract[151]|substance[154]	new[151]|giv[154]	coref	17-17[0_154]
16-37	2941-2945	eDNA	abstract[151]|substance[154]	new[151]|giv[154]	_	_
16-38	2946-2950	from	_	_	_	_
16-39	2951-2954	the	abstract[155]	new[155]	_	_
16-40	2955-2964	enzymatic	abstract[155]	new[155]	_	_
16-41	2965-2973	activity	abstract[155]	new[155]	_	_
16-42	2974-2976	of	abstract[155]	new[155]	_	_
16-43	2977-2982	DNase	abstract[155]|abstract	new[155]|new	ana	17-1
16-44	2983-2984	I	person	acc	_	_
16-45	2985-2987	in	_	_	_	_
16-46	2988-2996	breaking	_	_	_	_
16-47	2997-2999	up	_	_	_	_
16-48	3000-3003	the	substance[158]	giv[158]	coref	17-10[0_158]
16-49	3004-3011	biofilm	substance[158]	giv[158]	_	_
16-50	3012-3013	.	_	_	_	_

#Text=It cannot be dismissed that EVs produced from the biofilm phenotype may represent a shuttle for eDNA transport .
17-1	3014-3016	It	abstract	giv	_	_
17-2	3017-3023	cannot	_	_	_	_
17-3	3024-3026	be	_	_	_	_
17-4	3027-3036	dismissed	_	_	_	_
17-5	3037-3041	that	_	_	_	_
17-6	3042-3045	EVs	abstract	giv	coref	18-31
17-7	3046-3054	produced	_	_	_	_
17-8	3055-3059	from	_	_	_	_
17-9	3060-3063	the	quantity[162]	giv[162]	_	_
17-10	3064-3071	biofilm	substance|quantity[162]	giv|giv[162]	coref	18-50
17-11	3072-3081	phenotype	quantity[162]	giv[162]	_	_
17-12	3082-3085	may	_	_	_	_
17-13	3086-3095	represent	_	_	_	_
17-14	3096-3097	a	abstract[163]	new[163]	_	_
17-15	3098-3105	shuttle	abstract[163]	new[163]	_	_
17-16	3106-3109	for	abstract[163]	new[163]	_	_
17-17	3110-3114	eDNA	abstract[163]|abstract|abstract[165]	new[163]|giv|new[165]	_	_
17-18	3115-3124	transport	abstract[163]|abstract[165]	new[163]|new[165]	_	_
17-19	3125-3126	.	_	_	_	_

#Text=For all of these reasons , we aimed to optimize a simplified Polychromatic Flow Cytometry ( PFC ) method for a fast identification , enumeration and characterization of bacterial derived EVs , as well as for the analysis of their eDNA-associated subtypes , produced by the planktonic and the biofilm phenotypes of a Gram-negative ( H. pylori ATCC 43629 ) and a Gram-positive ( L. reuteri DSM 17938 ) bacterium .
18-1	3127-3130	For	_	_	_	_
18-2	3131-3134	all	abstract[166]	new[166]	_	_
18-3	3135-3137	of	abstract[166]	new[166]	_	_
18-4	3138-3143	these	abstract[166]	new[166]	_	_
18-5	3144-3151	reasons	abstract[166]	new[166]	_	_
18-6	3152-3153	,	_	_	_	_
18-7	3154-3156	we	person	acc	ana	19-1
18-8	3157-3162	aimed	_	_	_	_
18-9	3163-3165	to	_	_	_	_
18-10	3166-3174	optimize	_	_	_	_
18-11	3175-3176	a	abstract[170]|abstract[172]	new[170]|new[172]	appos|appos	18-17[0_170]|18-17[0_170]
18-12	3177-3187	simplified	abstract[170]|abstract[172]	new[170]|new[172]	_	_
18-13	3188-3201	Polychromatic	abstract|abstract[170]|abstract[172]	new|new[170]|new[172]	_	_
18-14	3202-3206	Flow	abstract|abstract[170]|abstract[172]	new|new[170]|new[172]	_	_
18-15	3207-3216	Cytometry	abstract[170]|abstract[172]	new[170]|new[172]	_	_
18-16	3217-3218	(	abstract[172]	new[172]	_	_
18-17	3219-3222	PFC	abstract|abstract[172]	giv|new[172]	coref	19-4
18-18	3223-3224	)	abstract[172]	new[172]	_	_
18-19	3225-3231	method	abstract[172]	new[172]	_	_
18-20	3232-3235	for	abstract[172]	new[172]	_	_
18-21	3236-3237	a	abstract[172]|abstract[173]|abstract[174]	new[172]|new[173]|new[174]	ana|ana	18-40[0_174]|18-40[0_174]
18-22	3238-3242	fast	abstract[172]|abstract[173]|abstract[174]	new[172]|new[173]|new[174]	_	_
18-23	3243-3257	identification	abstract[172]|abstract[173]|abstract[174]	new[172]|new[173]|new[174]	_	_
18-24	3258-3259	,	abstract[172]|abstract[174]	new[172]|new[174]	_	_
18-25	3260-3271	enumeration	abstract[172]|abstract[174]|abstract	new[172]|new[174]|new	coref	19-30[198_0]
18-26	3272-3275	and	abstract[172]|abstract[174]	new[172]|new[174]	_	_
18-27	3276-3292	characterization	abstract[172]|abstract[174]|abstract[176]	new[172]|new[174]|new[176]	_	_
18-28	3293-3295	of	abstract[172]|abstract[174]|abstract[176]	new[172]|new[174]|new[176]	_	_
18-29	3296-3305	bacterial	abstract[172]|abstract[174]|abstract[176]|substance	new[172]|new[174]|new[176]|giv	coref	19-32
18-30	3306-3313	derived	_	_	_	_
18-31	3314-3317	EVs	object	giv	coref	19-16
18-32	3318-3319	,	_	_	_	_
18-33	3320-3322	as	_	_	_	_
18-34	3323-3327	well	_	_	_	_
18-35	3328-3330	as	_	_	_	_
18-36	3331-3334	for	_	_	_	_
18-37	3335-3338	the	abstract[179]	new[179]	_	_
18-38	3339-3347	analysis	abstract[179]	new[179]	_	_
18-39	3348-3350	of	abstract[179]	new[179]	_	_
18-40	3351-3356	their	abstract[179]|abstract|abstract[181]	new[179]|giv|new[181]	_	_
18-41	3357-3372	eDNA-associated	abstract[179]|abstract[181]	new[179]|new[181]	_	_
18-42	3373-3381	subtypes	abstract[179]|abstract[181]	new[179]|new[181]	_	_
18-43	3382-3383	,	_	_	_	_
18-44	3384-3392	produced	_	_	_	_
18-45	3393-3395	by	_	_	_	_
18-46	3396-3399	the	abstract[182]	giv[182]	_	_
18-47	3400-3410	planktonic	abstract[182]	giv[182]	_	_
18-48	3411-3414	and	_	_	_	_
18-49	3415-3418	the	abstract[184]	giv[184]	_	_
18-50	3419-3426	biofilm	substance|abstract[184]	giv|giv[184]	_	_
18-51	3427-3437	phenotypes	abstract[184]	giv[184]	_	_
18-52	3438-3440	of	abstract[184]	giv[184]	_	_
18-53	3441-3442	a	abstract[184]|substance[185]	giv[184]|giv[185]	_	_
18-54	3443-3456	Gram-negative	abstract[184]|substance[185]	giv[184]|giv[185]	_	_
18-55	3457-3458	(	_	_	_	_
18-56	3459-3461	H.	person[186]	giv[186]	_	_
18-57	3462-3468	pylori	person[186]	giv[186]	_	_
18-58	3469-3473	ATCC	person[186]	giv[186]	_	_
18-59	3474-3479	43629	person[186]|quantity	giv[186]|new	_	_
18-60	3480-3481	)	_	_	_	_
18-61	3482-3485	and	_	_	_	_
18-62	3486-3487	a	substance[188]	new[188]	_	_
18-63	3488-3501	Gram-positive	substance[188]	new[188]	_	_
18-64	3502-3503	(	substance[188]	new[188]	_	_
18-65	3504-3506	L.	substance[188]	new[188]	_	_
18-66	3507-3514	reuteri	substance[188]	new[188]	_	_
18-67	3515-3518	DSM	substance[188]|abstract[189]	new[188]|giv[189]	_	_
18-68	3519-3524	17938	substance[188]|abstract[189]	new[188]|giv[189]	_	_
18-69	3525-3526	)	substance[188]	new[188]	_	_
18-70	3527-3536	bacterium	substance[188]|animal	new[188]|giv	_	_
18-71	3537-3538	.	_	_	_	_

#Text=We demonstrated that PFC can be used as a tool to study the modifications of EVs production under different environmental conditions , as well as for the detection and enumeration of bacterial derived EVs , and in particular eDNA-associated EVs , in clinical samples .
19-1	3539-3541	We	person	giv	_	_
19-2	3542-3554	demonstrated	_	_	_	_
19-3	3555-3559	that	_	_	_	_
19-4	3560-3563	PFC	object	giv	_	_
19-5	3564-3567	can	_	_	_	_
19-6	3568-3570	be	_	_	_	_
19-7	3571-3575	used	_	_	_	_
19-8	3576-3578	as	_	_	_	_
19-9	3579-3580	a	_	_	_	_
19-10	3581-3585	tool	_	_	_	_
19-11	3586-3588	to	_	_	_	_
19-12	3589-3594	study	_	_	_	_
19-13	3595-3598	the	abstract[193]	giv[193]	_	_
19-14	3599-3612	modifications	abstract[193]	giv[193]	_	_
19-15	3613-3615	of	abstract[193]	giv[193]	_	_
19-16	3616-3619	EVs	abstract[193]|abstract|abstract[195]	giv[193]|giv|giv[195]	coref|coref	19-34|19-34
19-17	3620-3630	production	abstract[193]|abstract[195]	giv[193]|giv[195]	_	_
19-18	3631-3636	under	abstract[193]|abstract[195]	giv[193]|giv[195]	_	_
19-19	3637-3646	different	abstract[193]|abstract[195]|abstract[196]	giv[193]|giv[195]|giv[196]	_	_
19-20	3647-3660	environmental	abstract[193]|abstract[195]|abstract[196]	giv[193]|giv[195]|giv[196]	_	_
19-21	3661-3671	conditions	abstract[193]|abstract[195]|abstract[196]	giv[193]|giv[195]|giv[196]	_	_
19-22	3672-3673	,	abstract[193]	giv[193]	_	_
19-23	3674-3676	as	abstract[193]	giv[193]	_	_
19-24	3677-3681	well	abstract[193]	giv[193]	_	_
19-25	3682-3684	as	abstract[193]	giv[193]	_	_
19-26	3685-3688	for	abstract[193]	giv[193]	_	_
19-27	3689-3692	the	abstract[193]|abstract[197]	giv[193]|new[197]	_	_
19-28	3693-3702	detection	abstract[193]|abstract[197]	giv[193]|new[197]	_	_
19-29	3703-3706	and	abstract[193]	giv[193]	_	_
19-30	3707-3718	enumeration	abstract[193]|abstract[198]	giv[193]|giv[198]	_	_
19-31	3719-3721	of	abstract[193]|abstract[198]	giv[193]|giv[198]	_	_
19-32	3722-3731	bacterial	abstract[193]|abstract[198]|substance	giv[193]|giv[198]|giv	_	_
19-33	3732-3739	derived	abstract[193]	giv[193]	_	_
19-34	3740-3743	EVs	abstract[193]|object	giv[193]|giv	coref	19-38[201_0]
19-35	3744-3745	,	abstract[193]	giv[193]	_	_
19-36	3746-3749	and	abstract[193]	giv[193]	_	_
19-37	3750-3752	in	abstract[193]	giv[193]	_	_
19-38	3753-3763	particular	abstract[193]|abstract[201]	giv[193]|giv[201]	_	_
19-39	3764-3779	eDNA-associated	abstract[193]|abstract[201]	giv[193]|giv[201]	_	_
19-40	3780-3783	EVs	abstract[193]|abstract[201]	giv[193]|giv[201]	_	_
19-41	3784-3785	,	abstract[193]|abstract[201]	giv[193]|giv[201]	_	_
19-42	3786-3788	in	abstract[193]|abstract[201]	giv[193]|giv[201]	_	_
19-43	3789-3797	clinical	abstract[193]|abstract[201]|object[202]	giv[193]|giv[201]|new[202]	_	_
19-44	3798-3805	samples	abstract[193]|abstract[201]|object[202]	giv[193]|giv[201]|new[202]	_	_
19-45	3806-3807	.	_	_	_	_
